Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
- 11 January 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 62 (6), 1411-1421
- https://doi.org/10.1080/10428194.2020.1869959
Abstract
To describe real-world treatment patterns and outcomes among adult patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMA), patients were identified in the SEER-Medicare database (01/2006–12/2016); 3,046 patients with MDS treated with HMA were included. An algorithm was developed to categorize patients into MDS risk groups: the majority of patients were classified as Higher-risk (70.9%), 8.0% as Intermediate-risk, and 21.1% as Unknown-risk. Overall, 77.4% of patients initiated azacitidine and 22.6% decitabine; they received an average of 5.1 index-HMA cycles, of which 90.9% were complete with a median cycle duration of 28 days. Median survival was 11.6, 18.4, and 19.1 months for the Higher-risk, Intermediate-risk, and Unknown-risk groups, respectively. Median time-to-AML transformation was 19.3 months for the Higher-risk group and 50.4 months for the Intermediate-risk group (not reached for Unknown-risk). Data highlight the unmet medical needs of patients with MDS treated with HMA, particularly for the Higher-risk MDS group.Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 42 references indexed in Scilit:
- Current therapy of myelodysplastic syndromesBlood Reviews, 2013
- Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromesLeukemia Research, 2011
- Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registriesBlood, 2011
- Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database studyCurrent Medical Research and Opinion, 2011
- Hypomethylating Agents and Other Novel Strategies in Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- Outcome of patients with myelodysplastic syndrome after failure of decitabine therapyCancer, 2010
- Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeBlood, 2007
- Myelodysplastic syndromesCancer, 2007
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006